Pipeline
Learn more about our R&D pipeline and ongoing trials below
Development Programs – Solid Tumor
Drug
Indication
Phase 1
Phase 2
Phase 3
Tislelizumab
(anti-PD-1)
1L NonSq NSCLC
1L Sq NSCLC
2/3L NSCLC
Neo/adj NSCLC
1L ES-SCLC
1L ESCC
2L ESCC
LA ESCC
1L GC/GEJC
1L NPC
1L HCC
1L UBC
2/3L HCC
1L NSCLC (subcutaneous formulation)
Ociperlimab
(anti-TIGIT)
1L PD-L1 high NSCLC
NSCLC dose confirmation
BG-685011
(CDK2 inhibitor)
BC and solid tumors
BGB-43395
(CDK4 inhibitor)
BC and solid tumors
BG-C90742
(B7H4-ADC)
BC and solid tumors
BGB-C354
(B7H3-ADC)
Solid tumors
LBL-0073
(anti-LAG3)
MSS-CRC
1L ESCC
Umbrella
(IO combinations)
1L NSCLCa
Neo/adj NSCLCa
2L+ NSCLCa
1L HNSCCa
Zanidatamab4
(anti-HER2 BsAb)
2L HER2+ BTC
1L HER2+ GEA
BGB-A445
(anti-OX40)
Melanoma, UC
BGB-15025
(HPK1 inhibitor)
Solid tumors
BGB-26808
(HPK1 inhibitor)
Solid tumors
BGB-24714
(SMAC mimetic)
Solid tumors
BGB-30813
(DGKζ inhibitor)
Solid tumors
BGB-A3055
(anti-CCR8)
Solid tumors
Pamiparib
(PARP 1/2 inhibitor)
2L MTx gBRCAm PSOC
Tarlatamab5
(DLL3 x CD3)
2L SCLC
1L-ES-SCLC
LS-SCLC
3L+ SCLC (initiation activities)
Xaluritamig5
(STEAP1 x CD3)
mCRPC
BGB-R046
(IL-15 prodrug)
Solid tumors
BGB-B3227
(MUC1 x CD16A BsAb)
Lung and GI
BGB-B2033
(GPC3 x 4-1BB)
Solid tumors
BG-C477
(CEA-ADC)
Lung and GI cancers (preclinical)
BGB-53038
(PanKRAS inhibitor 2G)
Lung and GI cancers (preclinical)
BG-C137
(FGFR2b ADC)
GI cancer (preclinical)
BGB-58067
(PRMT5 inhibitor)
Lung and GI cancers (preclinical)
BG-60366
(EGFR-targeted CDAC)
Lung cancer (preclinical)
Planned for 2024
Safety and efficacy have not been established for investigational products and/or uses.
Development Programs – Hematology
Drug
Indication
Phase 1
Phase 2
Phase 3
Zanubrutinib
(BTK inhibitor)
CLL/SLL
WM
R/R FL
R/R MZL
TN MCL
R/R MCL
R/R DLBCL with CD79B
Previously treated B-cell malignancies
Sonrotoclax
(BCL2 inhibitor)
TN CLLb
R/R WM
R/R CLL
R/R MCL
R/R MM with t(11;14)
AML/MDS
B-cell malignancies
BGB-16673
(BTK-targeted CDAC)
B-cell malignancies
R/R MCL and R/R CLL
BGB-21447
(BCL2 inhibitor)
B-cell malignancies
Tislelizumab
(anti-PD-1)
R/R cHL
Ociperlimab
(anti-TIGIT)
R/R DLBCL
Zanubrutinib
(BTK inhibitor)
Primary membranous nephropathy
Lupus nephritis
BGB-45035
(IRAK4-targeted CDAC)
Immunology & inflammation
Blinatumomab5
(CD3 X CD19)
Pediatric R/R BP-ALL
Safety and efficacy have not been established for investigational products and/or uses.
aMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.
bin combination with Zanubrutinib.
1Ensem collaboration; BeiGene has global rights.
2DualityBio collaboration; BeiGene has global rights.
3Leads Biolabs collaboration; BeiGene has ex-China commercial rights.
4Zymeworks/Jazz collaboration; BeiGene has APAC/ex Japan, AU, and NZ commercial rights.
5Amgen collaboration; BeiGene has China commercial rights.
1L, first line; 2L, second line; 3L, third line; 4-1BB, tumor necrosis factor receptor superfamily member 9; ADC, antibody-drug conjugate; AML, acute myeloid leukemia; BC, breast cancer; BCL2, B-cell lymphoma 2; BsAb, bispecific antibody; BP-ALL, B-cell precursor acute lymphoblastic leukemia; BTC, biliary tract cancer; BTK, Bruton tyrosine kinase; CCR8, the C-C motif chemokine receptor 8; CD3, cluster of differentiation 3; CD16A, Fc receptor FcγRIIIa; CD19, cluster of differentiation 19; CD79B, cluster of differentiation 79B; CDAC, chimeric degradation activating compound; CDK2, cyclin-dependent kinase 2; CDK4, cyclin-dependent kinase 4; CEA, carcinoembryonic antigen; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; DGKζ, diacylglycerol kinase ζ; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like ligand 3; EGFR, epidermal growth factor receptor; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; FGFR2b, fibroblast growth factor receptor 2, isoform IIIb; FL, follicular lymphoma; gBRCAm, germline BReast CAncer gene (BRCA) mutation; GC, gastric cancer; GEA, gastroesophageal adenocarcinomas; GEJC, gastroesophageal junction carcinoma; GI, gastrointestinal; GPC3, glypican-3; IL-15, interleukin-15; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; HPK1, hematopoietic progenitor kinase 1; IO, immunotherapy; IRAK4, interleukin-1 receptor-associated kinase 4; KRAS, Kirsten rat sarcoma virus; LA, locally advanced; LAG3, lymphocyte activation gene 3; LS-SCLC, limited-stage small cell lung cancer; MCL, mantle cell lymphoma; mCRPC, metastatic castration-resistant prostate cancer; MDS, myelodysplastic syndromes; MM, multiple myeloma; MSS, microsatellite stability; MTx, maintenance treatment; MUC1, mucin 1; PARP 1/2, poly (ADP-ribose) polymerase 1 and 2; MZL, marginal zone lymphoma; NPC, nasopharyngeal carcinoma; NonSq, non-squamous; NSCLC, non–small cell lung cancer; OX40, a member of the tumor necrosis factor (TNF) receptor family, also know as CD134; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PRMT5, protein arginine methyltransferase 5; PSOC, platinum-sensitive ovarian cancer; R/R, recurrent/refractory; SCLC, small cell lung cancer; SLL, small lymphocytic lymphoma; SMAC, second mitochondria-derived activator of caspase; STEAP1, six-transmembrane epithelial antigen of the prostate 1; Sq, squamous; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TN, treatment naive; UBC, urothelial bladder cancer; UC, urothelial carcinoma; WM, Waldenström macroglobulinemia.
Interactive Clinical Pipeline
Videos
Anti-OX40 Mechanism of Action
Anti-PD-1 Mechanism of Action
CDK4 Inhibitor Mechanism of Action
BTKI Mechanism of Action
Anti-TIGIT Mechanism of Action
PARPI Mechanism of Action
